These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1332094)

  • 21. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects.
    Krystal JH; Webb E; Cooney NL; Kranzler HR; Southwick SW; Heninger GR; Charney DS
    Am J Psychiatry; 1996 Jan; 153(1):83-92. PubMed ID: 8540598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts.
    Handelsman L; Kahn RS; Sturiano C; Rinaldi PJ; Gabriel S; Schmeidler JP; Bernstein DP; Siever L; Cooper TB
    Psychiatry Res; 1998 Jul; 80(1):1-12. PubMed ID: 9727959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study.
    Lawlor BA; Sunderland T; Mellow AM; Hill JL; Molchan SE; Murphy DL
    Arch Gen Psychiatry; 1989 Jun; 46(6):542-9. PubMed ID: 2730278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
    Lindenmayer JP; Adityanjee ; Vital-Herne M; Bark N; Grochowski S; Moynihan N
    Biol Psychiatry; 1997 Jul; 42(1):6-12. PubMed ID: 9193736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.
    Mueller EA; Murphy DL; Sunderland T
    Psychopharmacology (Berl); 1986; 89(3):388-91. PubMed ID: 3014595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S; John JP; Reddy LP
    Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.
    Kahn RS; Wetzler S; Asnis GM; Kling MA; Suckow RF; van Praag HM
    Psychiatry Res; 1991 Apr; 37(1):25-34. PubMed ID: 1650487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects.
    Seibyl JP; Krystal JH; Price LH; Woods SW; D'Amico C; Heninger GR; Charney DS
    Psychiatry Res; 1991 Sep; 38(3):227-36. PubMed ID: 1754635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
    Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms.
    Krystal JH; Webb E; Cooney N; Kranzler HR; Charney DS
    Arch Gen Psychiatry; 1994 Nov; 51(11):898-911. PubMed ID: 7944878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine.
    Sevy S; Brown SL; Wetzler S; Kotler M; Molcho A; Plutchik R; van Praag HM
    Psychiatry Res; 1994 Sep; 53(3):219-29. PubMed ID: 7870844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects.
    Kahn RS; Kling MA; Wetzler S; Asnis GM; van Praag H
    Psychopharmacology (Berl); 1992; 108(1-2):225-8. PubMed ID: 1410142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers.
    Sabbe B; Hulstijn W; Maes M; Pier M; Scharpé S; Zitman F
    Psychiatry Res; 2001 Dec; 105(3):151-63. PubMed ID: 11814535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.
    Charney DS; Woods SW; Goodman WK; Heninger GR
    Psychopharmacology (Berl); 1987; 92(1):14-24. PubMed ID: 3110824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia.
    Maes M; van West D; De Vos N; Westenberg H; Van Hunsel F; Hendriks D; Cosyns P; Scharpé S
    Neuropsychopharmacology; 2001 Jan; 24(1):37-46. PubMed ID: 11106874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin receptor sensitivity and aggression.
    Wetzler S; Kahn RS; Asnis GM; Korn M; van Praag HM
    Psychiatry Res; 1991 Jun; 37(3):271-9. PubMed ID: 1891509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
    Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.
    Silverstone PH; Cowen PJ
    Biol Psychiatry; 1994 Sep; 36(5):309-16. PubMed ID: 7993957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys.
    Aloi JA; Insel TR; Mueller EA; Murphy DL
    Life Sci; 1984 Apr; 34(14):1325-31. PubMed ID: 6708733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
    Feuchtl A; Bagli M; Stephan R; Frahnert C; Kölsch H; Kühn KU; Rao ML
    Pharmacopsychiatry; 2004 Jul; 37(4):180-8. PubMed ID: 15467976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.